ProAlgaZyme subfraction improves the lipoprotein profile of hypercholesterolemic hamsters, while inhibiting production of betaine, carnitine, and choline metabolites

Nutrition & Metabolism

Smiti V Gupta¹  Pramod Khosla¹  Nadia Saadat¹  Arvind Goja¹  Andreea Geamanu¹ 

[1] Nutrition and Food Science, 3009 Science Hall, Wayne State University, Detroit, MI 48202, USA

关键词: ProAlgaZyme;    Metabolomics;    Lipid metabolism;    ¹H NMR;    HDL;    Choline;    Carnitine;    Betaine;    Apolipoprotein A1;   

Others  :  803231
DOI  :  10.1186/1743-7075-10-55

 received in 2013-06-28, accepted in 2013-08-21,  发布年份 2013

【 摘 要 】

Background

Previously, we reported that ProAlgaZyme (PAZ) and its biologically active fraction improved plasma lipids in hypercholesterolemic hamsters, by significantly increasing the high density lipoprotein cholesterol (HDL-C) while reducing non-HDL cholesterol and the ratio of total cholesterol/HDL-C. Moreover, hepatic mRNA expression of genes involved in HDL/reverse cholesterol transport were significantly increased, while cholesteryl ester transfer protein (CETP) expression was partially inhibited. In the current study, we investigated the therapeutic efficacy of the biologically active fraction of PAZ (BaP) on the plasma lipid and plasma metabolomic profiles in diet induced hypercholesterolemic hamsters.

Methods

Fifty male Golden Syrian hamsters were fed a high fat diet for 4 weeks prior to randomization into 6 groups, based on the number of days they received subsequent treatment. Thus animals in T0, T3, T7, T10, T14, and T21 groups received BaP for 0, 3, 7, 10, 14, and 21 days, respectively, as their drinking fluid. Plasma lipids were assayed enzymatically, while real-time reverse transcriptase polymerase chain reaction (RT-PCR) provided the transcription levels of the Apolipoprotein (Apo) A1 gene. The plasma metabolomic profile was determined using ¹H nuclear magnetic resonance (NMR) spectroscopy in conjunction with multivariate analysis.

Results

Plasma HDL-C was significantly increased in T3 (P < 0.05) and T21 (P < 0.001), while non-HDL cholesterol was significantly reduced in T3, T7, T10 (P < 0.001) and T14, T21 (P < 0.01). Moreover, the ratio of total cholesterol/HDL-C was significantly lower in all BaP treated groups (P < 0.001) as compared with T0. Quantitative RT-PCR showed an increase in Apo A1 expression in T10 (3-fold) and T21 (6-fold) groups. NMR data followed by multivariate analysis showed a clear separation between T0 and T21 groups, indicating a difference in their metabolomic profiles. Plasma concentrations of metabolites associated with a risk for atherosclerosis and cardiovascular disease, including choline, phosphocholine, glycerol-phosphocholine, betaine and carnitine metabolites were significantly lower in the T21 group.

Conclusion

Treatment with BaP significantly improved the plasma lipid profile by increasing HDL-C and lowering non-HDL cholesterol. In addition, BaP potentially improved the plasma metabolomic profile by reducing the concentration of key metabolites associated with risk for atherosclerosis and cardiovascular disease.

【 授权许可】

   
2013 Geamanu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Jones ML, Tomaro-Duchesneau C, Martoni CJ, Prakash S: Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications. Expert Opin Biol Ther 2013, 13:631-642.
• [2]Bocanegra A, Bastida S, Benedi J, Nus M, Sanchez-Montero JM, Sanchez-Muniz FJ: Effect of seaweed and cholesterol-enriched diets on postprandial lipoproteinaemia in rats. Br J Nutr 2009, 102:1728-1739.
• [3]Chen J, Jiang Y, Ma KY, Chen F, Chen ZY: Microalga decreases plasma cholesterol by down-regulation of intestinal NPC1L1, hepatic LDL receptor, and HMG-CoA reductase. J Agric Food Chem 2011, 59:6790-6797.
• [4]Harding SV, Zhao HL, Marinangeli CP, Day AG, Dillon HF, Jain D, Jones PJ: Red algal cellular biomass lowers circulating cholesterol concentrations in Syrian golden hamsters consuming hypercholesterolaemic diets. Br J Nutr 2009, 102:842-847.
• [5]Misurcova L, Skrovankova S, Samek D, Ambrozova J, Machu L: Health benefits of algal polysaccharides in human nutrition. Adv Food Nutr Res 2012, 66:75-145.
• [6]Oben J, Enonchong E, Kuate D, Mbanya D, Thomas TC, Hildreth DJ, Ingolia TD, Tempesta MS: The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health. Lipids Health Dis 2007, 6:20. BioMed Central Full Text
• [7]Geamanu A, Saadat N, Goja A, Wadehra M, Ji X, Gupta SV: ProAlgaZyme and its subfractions increase plasma HDL cholesterol via upregulation of ApoA1, ABCA1, and SBR1, and inhibition of CETP in hypercholesterolemic hamsters. Nutr Dietary Suppl 2012, 4:17-24.
• [8]Ramsey SA, Gold ES, Aderem A: A systems biology approach to understanding atherosclerosis. EMBO Mol Med 2010, 2:79-89.
• [9]Doring Y, Noels H, Weber C: The use of high-throughput technologies to investigate vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 2012, 32:182-195.
• [10]Martin JC, Canlet C, Delplanque B, Agnani G, Lairon D, Gottardi G, Bencharif K, Gripois D, Thaminy A, Paris A: 1H NMR metabonomics can differentiate the early atherogenic effect of dairy products in hyperlipidemic hamsters. Atherosclerosis 2009, 206:127-133.
• [11]Coen M, Holmes E, Lindon JC, Nicholson JK: NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol 2008, 21:9-27.
• [12]Wei L, Liao P, Wu H, Li X, Pei F, Li W, Wu Y: Metabolic profiling studies on the toxicological effects of realgar in rats by (1)H NMR spectroscopy. Toxicol Appl Pharmacol 2009, 234:314-325.
• [13]Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, Fearnside J, Tatoud R, Blanc V, Lindon JC, et al.: Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA 2006, 103:12511-12516.
• [14]Walsh MC, Brennan L, Malthouse JP, Roche HM, Gibney MJ: Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans. Am J Clin Nutr 2006, 84:531-539.
• [15]Bertram HC, Hoppe C, Petersen BO, Duus JO, Molgaard C, Michaelsen KF: An NMR-based metabonomic investigation on effects of milk and meat protein diets given to 8-year-old boys. Br J Nutr 2007, 97:758-763.
• [16]Jove M, Ayala V, Ramirez-Nunez O, Serrano JC, Cassanye A, Arola L, Caimari A, Del Bas JM, Crescenti A, Pamplona R, Portero-Otin M: Lipidomic and metabolomic analyses reveal potential plasma biomarkers of early atheromatous plaque formation in hamsters. Cardiovasc Res 2013, 97:642-652.
• [17]Williams RE, Lenz EM, Lowden JS, Rantalainen M, Wilson ID: The metabonomics of aging and development in the rat: an investigation into the effect of age on the profile of endogenous metabolites in the urine of male rats using 1H NMR and HPLC-TOF MS. Mol Biosyst 2005, 1:166-175.
• [18]Dorfman SE, Wang S, Vega-Lopez S, Jauhiainen M, Lichtenstein AH: Dietary fatty acids and cholesterol differentially modulate HDL cholesterol metabolism in Golden-Syrian hamsters. J Nutr 2005, 135:492-498.
• [19]Yang H, Pang W, Lu H, Cheng D, Yan X, Cheng Y, Jiang Y: Comparison of metabolic profiling of cyanidin-3-O-galactoside and extracts from blueberry in aged mice. J Agric Food Chem 2011, 59:2069-2076.
• [20]Fardet A, Canlet C, Gottardi G, Lyan B, Llorach R, Remesy C, Mazur A, Paris A, Scalbert A: Whole-grain and refined wheat flours show distinct metabolic profiles in rats as assessed by a 1H NMR-based metabonomic approach. J Nutr 2007, 137:923-929.
• [21]Eriksson L, Andersson PL, Johansson E, Tysklind M: Megavariate analysis of environmental QSAR data. Part II–investigating very complex problem formulations using hierarchical, non-linear and batch-wise extensions of PCA and PLS. Mol Divers 2006, 10:187-205.
• [22]Pears MR, Cooper JD, Mitchison HM, Mortishire-Smith RJ, Pearce DA, Griffin JL: High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease. J Biol Chem 2005, 280:42508-42514.
• [23]Qiao-feng W, Ling-ling G, Shu-guang Y, Qi Z, Sheng-feng L, Fang Z, Hai-yan Y, Yong T, Xian-zhong Y: A(1)H NMR-based metabonomic study on the SAMP8 and SAMR1 mice and the effect of electro-acupuncture. Exp Gerontol 2011, 46:787-793.
• [24]Weljie AM, Newton J, Mercier P, Carlson E, Slupsky CM: Targeted profiling: quantitative analysis of 1H NMR metabolomics data. Anal Chem 2006, 78:4430-4442.
• [25]Grundy SM: Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998, 81:18B-25B.
• [26]Castelli WP, Anderson K, Wilson PW, Levy D: Lipids and risk of coronary heart disease. The Framingham study. Ann Epidemiol 1992, 2:23-28.
• [27]Hanukoglu I: Steroidogenic enzymes: structure, function, and role in regulation of steroid hormone biosynthesis. J Steroid Biochem Mol Biol 1992, 43:779-804.
• [28]de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJ: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose–response study. Circulation 2002, 105:2159-2165.
• [29]Jones RD, Repa JJ, Russell DW, Dietschy JM, Turley SD: Delineation of biochemical, molecular, and physiological changes accompanying bile acid pool size restoration in Cyp7a1(−/−) mice fed low levels of cholic acid. Am J Physiol Gastrointestin Liver Physiol 2012, 303:G263-G274.
• [30]Kang SM, Park JC, Shin MJ, Lee H, Oh J, Ryu do H, Hwang GS, Chung JH: (1)H nuclear magnetic resonance based metabolic urinary profiling of patients with ischemic heart failure. Clin Biochem 2011, 44:293-299.
• [31]Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ: Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res 2010, 51:1546-1553.
• [32]Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, et al.: Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472:57-63.
• [33]Heather LC, Wang X, West JA, Griffin JL: A practical guide to metabolomic profiling as a discovery tool for human heart disease. J Mol Cell Cardiol 2013, 55:2-11.
• [34]Bremer J: Carnitine–metabolism and functions. Physiol Rev 1983, 63:1420-1480.
• [35]Rebouche CJ, Seim H: Carnitine metabolism and its regulation in microorganisms and mammals. Annu Rev Nutr 1998, 18:39-61.
• [36]Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, et al.: Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013, 19:576-585.